New drug combination before surgery for HR+ HER2-low breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- Your breast cancer must be hormone receptor-positive (HR+) and HER2-low (a specific type of HER2).
- You cannot have had any prior treatment for your breast cancer (like chemotherapy, radiation, or hormone therapy).
- Your cancer must be at stage II or III (not spread to distant parts of the body).
- You need to be in fairly good health, with normal organ function (liver, kidney, heart).
- You must not have had any other cancer in the past 5 years (except for certain curable skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two newer drugs to standard chemotherapy can improve outcomes for women with early-stage breast cancer that is hormone-receptor positive and has low HER2. The goal is to see if a combination of immunotherapy and targeted therapy helps shrink tumors before surgery.
This study tests a new combination of treatments given before surgery for breast cancer that is hormone-receptor positive and HER2-low. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes. You might be eligible if you have not yet had any treatment for breast cancer.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
This trial tests a new combination of two targeted drugs given before surgery to shrink HER2-positive breast cancer. It may help make surgery more successful and reduce the chance of the cancer coming back.
Hear when a new HR Positive/HER2 Low Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.